---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-026924"
form_type: "8-K"
ticker: "LIXT"
cik: "0001335105"
company_name: "LIXTE BIOTECHNOLOGY HOLDINGS, INC."
filed_at: "2024-07-11T23:59:59+00:00"
generated_at: "2026-05-31T21:44:11.254895+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "medium"
source: SEC EDGAR
---

# Lixte Biotechnology switches director compensation from cash to stock options for Q2-Q4 2024 to preserve cash

## Summary
- Director Rene Bernards agrees to receive equity compensation instead of cash starting Q2 2024, aligning with other non-officer directors.
- Board Compensation Plan amended: non-officer directors will receive stock options for Q2, Q3, Q4 2024 in lieu of cash.
- Options vest immediately, expire in 5 years; exercise price based on quarter-end closing market price.
- Change intended to preserve cash; Board and Compensation Committee may extend beyond Q4 2024.

## SEC filing metadata
- accession: 0001493152-24-026924
- form_type: 8-K
- ticker: LIXT
- cik: 0001335105
- company_name: LIXTE BIOTECHNOLOGY HOLDINGS, INC.
- filed_at: 2024-07-11T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: medium
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1335105/000149315224026924/0001493152-24-026924-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1335105/000149315224026924/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-026924
- JSON: https://secwatch.observer/filing/0001493152-24-026924.json
- Plain text: https://secwatch.observer/filing/0001493152-24-026924.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.